Measles virus used to treat bone marrow cancer
ConclusionThis research has shown that a modified measles virus can produce a long-term remission of cancerous lesions in a person with multiple myeloma that has not responded to chemotherapy. Patients such as this have limited remaining treatment options, so a new treatment would offer an important development.The article describes the response of two women in a phase I trial who received the highest dose of the virus. One of the women had a lasting response; the other woman showed some signs of an early response, but these were not as good and were not as long-lasting. As yet, we don’t know what proportion of patients ...
Source: NHS News Feed - May 16, 2014 Category: Consumer Health News Tags: Cancer Medical practice Source Type: news
Encouraging New Research About Virotherapy for Myeloma
The IMF is very pleased to see research from Dr. Stephen Russell at the Mayo Clinic achieving success and starting to make a difference for patients. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 16, 2014 Category: Hematology Source Type: news
Mayo Clinic First to Show Virotherapy is Promising Against Multiple Myeloma (pkg)
https://www.youtube.com/watch?v=LImk-KdMT1w ROCHESTER, Minn. — May 14, 2014 — In a proof of principle clinical trial, Mayo Clinic researchers have demonstrated that virotherapy — destroying cancer with a virus that infects and kills cancer cells but spares normal tissues — can be effective against the deadly cancer multiple myeloma. The findings appear in the journal Mayo Clinic [...] (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - May 16, 2014 Category: Hospital Management Source Type: news
“Massive Dose of Measles Vaccine Clears Woman's Cancer,” USAToday.com
Mayo Clinic Cancer Center researchers announced a landmark study where a massive dose of the measles vaccine, enough to inoculate 10 million people, wiped out a Minnesota woman's incurable blood cancer.
The Mayo Clinic Cancer Center-one of the 25 NCCN Member Institutions—conducted the clinical trial last year using virotherapy. The method discovered the measles virus wiped out multiple myeloma cancer calls. Researchers engineered the measles virus (MV-NIS) in a single intravenous dose, making i... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - May 15, 2014 Category: Cancer & Oncology Source Type: news
Ludwig researchers show that infecting just 1 tumor with a virus could boost the systemic effectiveness of cancer immunotherapy
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 9, 2014 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Researchers show that infecting just one tumor with a virus could boost the systemic effectiveness of cancer immunotherapy
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 7, 2014 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Going viral to target tumors
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 5, 2014 Category: Cancer & Oncology Source Type: news
Oncolytic Adenovirus Characterization: Activity and Immune Responses
Virotherapy in one of the main current applications of recombinant adenoviruses. Oncolytic adenovirus are designed to target tumors, replicate selectively in tumor cells, and elicit immune responses against tumor antigens. Transgene expression in replication-competent oncolytic vectors allows to explore multiple strategies to enhance the potential of virotherapy. In this chapter we describe common in vivo and in vitro techniques used to evaluate the potency and biodistribution of oncolytic viruses. Monitoring immune responses against viral and tumor antigens is crucial as the immune system determines the outcome of virothe...
Source: Springer protocols feed by Microbiology - October 24, 2013 Category: Microbiology Source Type: news
Two medical pioneers aim to trial a cancer-killing virus. I aim to help out | Alexander Masters
A pair of researchers in Sweden may have a revolutionary cancer treatment on their hands. But a separate revolution will be needed to get it to marketJust north of Stockholm, among the creaking Swedish ice-forests, three revolutions for 2013 are taking place.Revolution One: Two researchers at the University of Uppsala have engineered a virus that will attack cancer. Cheap, precise, with only mild, flu-like side-effects, this plucky little microbe sounds too good to be true. Yet in peer-reviewed articles in top journals, Professor Magnus Essand and Dr Justyna Leja have repeatedly showed that Ad5[CgA-E1A-miR122]PTD views hea...
Source: Guardian Unlimited Science - January 4, 2013 Category: Science Authors: Alexander Masters Tags: Comment The Guardian Crowdsourcing Health Medical research Society Technology Kickstarter Features Cancer Internet Science Comment is free Source Type: news
